Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 3/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20806109 | 0.91 | FURIN (0.45) | FURINSIRT1HTTSMN1; SMN2SIRT2 | |
| SCHEMBL24611248 | 0.91 | FURIN (0.45) | FURINSIRT1HTTSMN1; SMN2SIRT2 | |
| SCHEMBL20739105 | 0.90 | NPY4R (0.38) | FURINSIRT1HTTNPY4RNPY1R | |
| SCHEMBL12944390 | 0.90 | NPY4R (0.38) | FURINSIRT1HTTNPY4RNPY1R | |
| SCHEMBL20158427 | 0.90 | NPY4R (0.38) | FURINSIRT1HTTNPY4RNPY1R | |
| SCHEMBL15692085 | 0.90 | NPY4R (0.38) | FURINSIRT1HTTNPY4RNPY1R | |
| SCHEMBL22315797 | 0.90 | NPY4R (0.38) | FURINSIRT1HTTNPY4RNPY1R | |
| SCHEMBL84332 | 0.90 | NPY4R (0.38) | FURINSIRT1HTTNPY4RNPY1R | |
| SCHEMBL7607468 | 0.90 | NPY4R (0.38) | FURINSIRT1HTTNPY4RNPY1R | |
| SCHEMBL12634420 | 0.90 | TAAR1 (0.41) | SIRT1NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2023280227-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYTH3, CD47, FCGRT | FURIN 147/4885SIRT1 3764/4885HTT 1812/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | FURIN 1847/4885SIRT1 3292/4885HTT 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.